Thiamine-Responsive and Non-responsive Patients with PDHC-E1 Deficiency: A Retrospective Assessment
- 10 April 2014
- book chapter
- Published by Springer Nature
- Vol. 15, 1-15
Abstract
Pyruvate dehydrogenase complex (PDHC) deficiency is a disorder of energy metabolism that leads to a range of clinical manifestations. We sought to characterise clinical manifestations and biochemical, neuroimaging and molecular findings in thiamine-responsive and nonresponsive PDHC-deficient patients and to identify potential pitfalls in the diagnosis of PDHC deficiency. We retrospectively reviewed all medical records of all PDHC-deficient patients (n = 19; all had PDHA1 gene mutations) and one patient with severe PDHC deficiency secondary to 3-hydroxyisobutyryl-CoA hydrolase deficiency managed at our centre between 1982 and 2012. Responsiveness to thiamine was based on clinical parameters. Seventeen patients received thiamine treatment: eight did not respond, four showed sustained response and the others responded temporarily/questionably. Sustained response was noted at thiamine doses >400 mg/day. Age at presentation was 0–6 and 12–27 months in the nonresponsive (n = 8) and responsive (n = 4) patients, respectively. Corpus callosum abnormalities were noted in 4/8 nonresponsive patients. Basal ganglia involvement (consistent with Leigh disease) was found in four patients (including 2/4 thiamine-responsive patients). Diagnosis through mutation analysis was more sensitive and specific than through enzymatic analysis. We conclude that patients presenting at age >12 months with relapsing ataxia and possibly Leigh syndrome are more likely to be thiamine responsive than those presenting with neonatal lactic acidosis and corpus callosum abnormalities. However, this distinction is equivocal and treatment with thiamine (>400 mg/day) should be commenced on all patients suspected of having PDHC deficiency. Mutation analysis is the preferable first-line diagnostic test to avoid missing thiamine-responsive patients and misdiagnosing patients with secondary PDHC deficiency. Short Summary: Thiamine responsiveness is more likely in patients presenting at age >12 months with relapsing ataxia and possibly Leigh syndrome than in those presenting with neonatal lactic acidosis and corpus callosum abnormalities. Thiamine doses >400 mg/day are required for sustained response. Mutation analysis is more sensitive and specific than enzymatic analysis as a first-line diagnostic test.Keywords
This publication has 36 references indexed in Scilit:
- Intermittent‐relapsing pyruvate dehydrogenase complex deficiency: a case with clinical, biochemical, and neuroradiological reversibilityDevelopmental Medicine & Child Neurology, 2011
- A Korean Female Patient with Thiamine-responsive Pyruvate Dehydrogenase Complex Deficiency Due to a Novel Point Mutation (Y161C)in the PDHA1 GeneJournal of Korean Medical Science, 2006
- Biochemical and genetic studies of four patients with pyruvate dehydrogenase E1α deficiencyHuman Genetics, 1997
- Recurrent Muscle Weakness and Ataxia in Thiamine-Responsive Pyruvate Dehydrogenase Complex DeficiencyJournal of Child Neurology, 1997
- Pyruvate dehydrogenase deficiency in a child responsive to thiamine treatmentActa Paediatrica, 1996
- Pyruvate dehydrogenase complex deficiency due to a point mutation (P188L) within the thiamine pyrophosphate binding loop of the E1α subunitHuman Molecular Genetics, 1995
- X‐linked pyruvate dehydrogenase E1α subunit deficiency in heterozygous females: Variable manifestation of the same mutationJournal of Inherited Metabolic Disease, 1992
- Thiamine Responsive Pyruvate Dehydrogenase DeficiencyJournal of Nutritional Science and Vitaminology, 1992
- Variable clinical presentation in patients with defective E1 component of pyruvate dehydrogenase complexThe Journal of Pediatrics, 1987
- Function of the nonidentical subunits of mammalian pyruvate dehydrogenaseBiochemical and Biophysical Research Communications, 1972